About Participation in the Open Label Extension Study
Participating in the Open Label Extension
Upon completion of either ACT-AD or LIFT-AD study, interested participants are eligible to enroll in the Open Label Extension study of ATH-1017. This study provides an opportunity for interested participants to receive the active drug during this study. Active participants in the OLEX Study will remain blinded to their randomized study drug assignment in either the ACT-AD or LIFT-AD trial. The dosing schedule is the same as in ACT-AD or LIFT-AD. Participation in the study takes about eight months including approximately six months of treatment duration.
What is Involved in the Trials?
The study team will go over the detailed study information and criteria. You and your caregiver will be asked to sign consent forms if you decide to participate in the study.
Study Drug Assignment
Participants will be assigned to receive ATH-1017.
During the study duration, including approximately six months of treatment and two weeks of safety follow-up, participants will return to the clinical site for scheduled visits every one to six weeks. These visits will include tests to evaluate your memory conditions and will also include blood draws to evaluate safety.